Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Before he could help countless patients battle cystic fibrosis over a decades-long medical career, H. Joel Schmidt had to ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Travis Flores accused Baldoni of copyright infringement and breach of contract over the movie, which he claimed ripped off ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...